Dr. Robin Augustus Robinson (born 1955)
Wikipedia 🌐 NONE
Note : Almost all references to any "Robin A. Robinson" in US newspapers 2000 - 2022 have been removed.
https://www.renovacareinc.com/rc-team/robin-robinson/
Dr. Robin A. Robinson is a respected authority on the development of breakthrough biomedical technologies, and a seasoned expert in consummating collaborations with leading US government agencies, Fortune 500 companies, academic research groups, and foreign governments, for which he was cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker.
Notably, Dr. Robinson was appointed as the first Director of the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services, with an annual budget of $1.35 billion and a staff of 250 scientists and medical experts. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices for man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of these medical countermeasure products that BARDA supported were approved and licensed by the FDA during his 12-year tenure.
He concurrently served as Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services (Washington, D.C.), under appointment by HHS Secretary Michael Leavitt. Prior to his public service work at BARDA, he served as Director vaccines at Novavax, Inc. resulting in the discovery and development of more than 12 vaccine candidates. Before entering the pharmaceutical industry, he was an assistant professor in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School conducting research on the molecular pathogenesis of herpesviruses and HIV-1.
During his tenure at BARDA, Dr. Robinson initiated over $535 million in contracts for skin regeneration, burns, stem cell therapies, and related technologies to treat thermal and radiation burn wounds.
Dr. Robin Robinson is a consummate deal maker, having successfully established over 60 partnerships with federal agencies, including the United States Food & Drug Administration (FDA), Centers for Disease Control and Prevention, National Institutes of Health, US Army Medical Research Institute of Infectious Diseases, The Defense Advanced Research Projects Agency (DARPA), The Joint Program Executive Office for Chemical and Biological Defense, and the Defense Threat Reduction Agency.
His more than 80 non-governmental and commercial partnerships included the Gates Foundation, Wellcome-Trust, Sanofi, GlaxoSmithKline plc, Novartis, Merck, Roche/Genentech, Amgen, Johnson & Johnson (Crucell), SIGA, Regeneron and Emergent and many others.
Dr. Robinson has developed collaborations with universities and foreign governments, including the Johns Hopkins University, North Carolina State, and the United Kingdom, Canada, Australia, France, Germany, and others.
At RenovaCare, Dr. Robinson is responsible for setting the Company’s scientific strategy and leading our scientific and engineering teams in research & development activities. Dr. Robinson is a key participant in new product innovation and development and is charged with advancing the Company’s technology along its FDA submission pathway.
Dr. Robinson oversees and directs RenovaCare strategy, execution and engagement with government agencies, contract research organizations, academic institutions and select opinion leaders.
Dr. Robinson Chairs the RenovaCare Scientific Advisory Board.
RenovaCare Appoints Founding Director of BARDA Dr. Robin A. Robinson to Chief Scientific Officer
May 26, 2020 08:30 ET | Source: RenovaCare, Inc.
ROSELAND, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its Vice President, Scientific Affairs, Dr. Robin A. Robinson will now serve in a new and expanded full-time role as the Company’s Chief Scientific Officer. Prior to joining RenovaCare, Dr. Robinson served as founding Director of the Biomedical Advanced Research and Development Authority (BARDA) that leads development and stockpiling of medical countermeasures for national preparedness and response to man-made threats, pandemic influenza, and emerging infectious agents.
“With Dr. Robinson now full time at the helm of our science, research and development programs, along with the support of our scientific and engineering teams, we continue enhancing our capabilities and uncovering cell-spray breakthroughs to enable first-in-class regenerative therapies,” stated Mr. Alan L. Rubino, CEO & President of RenovaCare, Inc.
Dr. Robinson joins the executive management team and is responsible for setting the scientific strategy and priorities and leading R&D at RenovaCare. He will also interface with the intellectual property group for new products innovation and development, and with the Company’s regulatory teams to advance its FDA submission pathway. Dr. Robinson will additionally Chair the RenovaCare Scientific Advisory Board.
“From the beginning, I’ve been impressed by the scientific integrity and therapeutic promise of RenovaCare innovative cell isolation and spray therapy technologies for burns and wounds. Looking ahead, the prospect of isolating multiple cell types from many tissues for ultra-gentle spray administration using our patented SkinGun™, unlocks compelling clinical indications that may extend far beyond the regeneration of skin,” stated Dr. Robin A. Robinson.
“Dr. Robinson brings us seasoned managerial capabilities along with extensive depth of knowledge and experience with tissue regeneration and cell-based therapies for thermal and radiation burns, deep tissue wounds, and diabetic ulcers. He is also a respected authority, with special insights into product development, regulatory affairs, and breakthrough biomedical technologies,” concluded Mr. Rubino.
Notably, during his prior tenure at BARDA Dr. Robinson concurrently served as Deputy Assistant Secretary, U.S. Department of Health and Human Services. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices by industry partners with 38 approved and licensed by the FDA during his 12-year tenure. He led the nation’s medical countermeasure efforts against the avian influenza H5N1 threat (2004-2008), the H1N1 pandemic (2009), Ebola epidemic (2014), and Zika epidemic (2015). For these efforts, he was recognized in 2018 as one of the top 100 Champions for Change in medicine by the Medicine Maker.
During his tenure at BARDA, Dr. Robinson oversaw the support for development of many stem cell and other therapies for thermal and radiation burn wounds and acute radiation syndrome illnesses.
Prior to his appointment as RenovaCare Chief Scientific Officer, Dr. Robinson served as Vice President Scientific Affairs at the Company in a part-time consulting capacity since August 2019. As Chief Scientific Officer, Dr. Robinson joins the executive leadership team in a full time position, with substantially expanded research and development responsibilities at RenovaCare.
Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™ and CellMist™ System, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
For additional information, please call Amit Singh at: 888-398-0202 or visit:
To receive future press releases via email, please visit:
https://renovacareinc.com/investors/register/
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
Follow us on Twitter: https://twitter.com/RenovaCareInc
Follow us on Facebook: https://www.facebook.com/renovacarercar
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders, and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
LinkedIn
Facebook
Twitter
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products based on its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Dr. Robin Robinson, Founding Director of BARDA Joins RenovaCare
August 20, 2019 08:30 ET | Source: RenovaCare, Inc.
SCOTTSDALE, Ariz., Aug. 20, 2019 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of its Vice President of Scientific Affairs, Dr. Robin A. Robinson, a respected authority on the development of breakthrough biomedical technologies, for which he was cited in 2018 as one of the top 100 innovators in medicine by The Medicine Maker.
Notably, Dr. Robinson was appointed as Director of the Biomedical Advanced Research and Development Authority (BARDA), with an annual budget of $1.35 billion and a staff of 250 scientists and medical experts. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices for man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of these medical countermeasure products that BARDA supported were approved and licensed by the FDA during his 12-year tenure.
During his tenure at BARDA, Dr. Robinson oversaw the funding of over $535 million in contracts for skin regeneration, burns, stem cell therapies, and related technologies for thermal and radiation burn wounds.
At RenovaCare, Dr. Robinson will oversee and direct the Company’s strategy, execution and engagement with government agencies, commercial research groups, academic institutions and select opinion leaders.
“The patented RenovaCare SkinGun™ technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies,” stated Dr. Robin Robinson, newly appointed Vice President of Scientific Affairs at RenovaCare, Inc.
“I look forward to working with the RenovaCare team as we capitalize on this very exciting cell deposition innovation.”
“We’re privileged to have won Dr. Robinson’s confidence in our SkinGun™ technology, especially as we advance our regulatory program, push towards eventual commercialization, and expand our product and clinical pipelines,” stated Mr. Jay S. Bhogal, Chief Operating Officer at RenovaCare.
Dr. Robinson’s appointment follows last week’s award of a new patent to RenovaCare, allowing its SkinGun™ to now spray all varieties of tissues and cells, and thus opening the door for its potential application in regenerative applications beyond skin.
Recent breakthroughs in stem cell therapies include the regeneration of human organs, tissues and bone. RenovaCare believes that the ultra-gentle spray-on application of such cells could be investigated and developed by way of commercial and academic collaborations, an area of Dr. Robinson’s expertise.
Dr. Robin Robinson is a consummate dealmaker, having successfully established over 60 partnerships with federal agencies, including the United States Food & Drug Administration (FDA), Centers for Disease Control and Prevention, National Institutes of Health, The Defense Advanced Research Projects Agency (DARPA), The Joint Program Executive Office for Chemical and Biological Defense, and the Defense Threat Reduction Agency.
His non-governmental and more than 80 commercial partnerships included the Gates Foundation, Wellcome-Trust, Sanofi, GlaxoSmithKline plc, Novartis, Merck, Roche/Genentech, Amgen, Johnson & Johnson (Crucell), SIGA, Regeneron and Emergent.
Dr. Robinson developed collaborations with universities and foreign governments, including the Johns Hopkins University, North Carolina State University, and the United Kingdom, Canada, Australia, France, Germany, and others.
In addition to serving as Director of BARDA, Dr. Robinson was concurrently appointed Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services (Washington, D.C.), by HHS Secretary Michael Leavitt.
Prior to his public service work at BARDA, he served as Director vaccines at Novavax, Inc. resulting in the discovery and development of more than 12 vaccine candidates. Before entering the pharmaceutical industry, he was an assistant professor in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School conducting research on the molecular pathogenesis of herpesviruses and HIV-1. There he developed techniques to grow keratinocytes in tissue culture from fresh skin biopsies.
Spraying Skin Stem Cells onto Burns and Wounds
To date, over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the Company’s SkinGun™, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options, such as in-vitro cultured epithelial grafts that require a specialized and expensive external laboratory.
Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially weeks of hospitalization. Clinical outcomes of early experimental treatments have been peer-reviewed and published in several medical journals, including Burns and Annals of Plastic Surgery.
Patients who undergo skin grafting, today’s default treatment of care, can remain hospitalized for weeks and even months, and often enduring painful and costly surgeries and prolonged physical therapy. Some of these patients may also suffer from the psychological effects of disfigurement caused by permanent scarring and often cope with the ongoing use of pain medications and protracted joint mobility issues.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
About RenovaCare
RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
For additional information, please call Amit Singh at: 888-398-0202 or visit: http://renovacareinc.com
To receive future press releases via email, please visit: http://renovacareinc.com/investors/register/
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
Follow us on Twitter: https://twitter.com/RenovaCareInc
Follow us on Facebook: https://www.facebook.com/renovacarercar
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
LinkedIn
Facebook
Twitter
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company's technologies, technical problems with the Company's research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/96ff6f7b-2ae2-434a-84a1-19a2b35f0543
If 65 as of 2022 ... then born 1957 ...
Name : Robin A Robinson / Robin A Mrobinson] / [Robin Ada Michelle Robinson] / [Robin M Pegram] / [Robin Michelle Robinson] / [Robn Am Robinson]
Birth Date : Oct 1957
Residence Date : 1985-2017
Address : 1361 Downing St Ne / Washington, District of Columbia, USA / 20018
Second Residence Date : 2000-2016
Second Address : 1349 Randolph St NW / Washington, District of Columbia, USA / 20011
Third Residence Date : 2006-2011
Third Address : 104 Michigan Ave Ne Apt 43c / Washington, District of Columbia, USA / 20017
Fourth Residence Date : 1984-2008
Fourth Address : 8960 Congress Pl / Landover, Maryland, USA / 20785
Another biorth date ... https://www.ancestry.com/discoveryui-content/view/379223660:1788?tid=&pid=&queryId=a114bd5908d1910d297e99a24b84f6d6&_phsrc=kyz51&_phstart=successSource
Robin A Robinson in the U.S., Public Records Index, 1950-1993, Volume 1
Name : Robin A Robinson / [Robin Robinson]
Birth Date : 19 Apr 1955 / [19 Oct 1957]
Residence Date : 1990
Address: 1361 Downing St NE / Washington, DC / 20018-1136
[...]
Third Residence Date : 1993
Third Address : 814 Ivy Way / Frederick, MD / 21701-9268
Fourth Address : 8960 Congress Pl / Landover, MD / 20785-4726
https://www.congress.gov/116/meeting/house/110242/witnesses/HHRG-116-SY00-Bio-RobinsonR-20191120.pdf
2019-11-20-usa-gov-congress-meeting-witness-hhrg-116-sy00-bio-robinson-r.pdf
Biosketch
ROBIN ROBINSON, Ph.D.
Dr. Robin Robinson currently serves as Vice President of Scientific Affairs for RenovaCare, Inc. directing development of cellular therapies for wound healing. Concurrently he is a Fellow for Regenerative Medicine and Biomedical Research at the Thought Leadership and Innovation (TLI) Foundation on regenerative medicines and independent consultant on vaccines and biodefense matters.
He reentered the biopharmaceutical business sector after retiring in 2016 from federal public service at the U.S. Department of Health and Human Services, where he served from 2008 - 2016 as the first director of the Biomedical Advanced Research and Development Authority (BARDA) and Deputy Assistant Secretary for Preparedness and Response and as BARDA’s Influenza and Emerging Disease program director (2004-2008). Dr. Robinson brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of drugs, vaccines, diagnostics, and medical devices to address the deleterious outcomes of man-made biodefense threats, pandemic influenza, and emerging infectious diseases including Ebola and Zika viruses. 32 of its 250+ medical countermeasure products that BARDA supported since 2008 were fully approved and licensed by the FDA during his tenure; today that total is 52. Dr. Robinson established a pandemic influenza program with scientific and technical experts to implement the national and global strategic plans and policies for the development of new influenza antiviral drugs, vaccines, and diagnostics outlined in the National Strategy for Pandemic Influenza. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense’s Clay Dalrymple Award in 2008, the HHS Distinguished Service Award three times, and a finalist for the Service to America Medal in 2009. In 2013-2015 Dr. Robinson was recognized as one of the top 50 most influential persons worldwide in vaccines by Vaccine Nation. In 2018 Dr. Robinson was recognized by Medicine Maker as one of the top 100 innovators in medicine.
Dr. Robinson received a Bachelor of Sciences degree in Biology from Millsaps College in 1976, a Doctoral degree in 1981 from the University of Mississippi Medical School in medical microbiology under Dr. Dennis O’Callaghan on herpesvirus oncogenesis, and completed in 1983 a NIH postdoctoral fellowship at the State University of New York at Stony Brook under Dr. Arnold Levine on molecular mechanisms in oncology. Dr. Robinson pursued his own research as a faculty member in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School from 1983-1992 on the molecular pathogenesis of herpesviruses and HIV. Prior to federal public service, Dr. Robinson served as the Director of Vaccines at Novavax, Inc. (Rockville, MD) from 1995-2004, where he led the development of 20+ vaccines to hepatitis B and E, influenza, HIV, noroviruses, and human papilloma viruses from early development, clinical trials, manufacturing scale-up, and commercialization through FDA licensure. While at Novavax, he developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers.
Dr. Robinson also served on the Senior Advisory Group for the World Health Organization (WHO) on emerging infectious diseases and pandemic influenza. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.
[researcher note ... graduaiton in 1976, suggests a birth year of 1955 ...
2022-11-15-ancestry-com-directory-info-dr-robin-a-robinson-1181285558.pdf
Dr Robin A Robinson in the U.S., Public Records Index, 1950-1993, Volume 1
Name : Dr Robin A Robinson / [Dr Robin Robinson]
Birth Date : Apr 1955 / [Apr 1955]
Residence Date : 1992
Address: 22 Fifeshire CT / Gaithersburg, MD / 20886-0476
Second Residence Date : 1993
Second Address : 303 N Summit Ave / Gaithersburg, MD / 20877-3169
Third Residence Date : 1996
Third Address : 303 N Summit Ave # 2 / Gaithersburg, MD / 20877-3169
Fourth Address : 814 Jay WY 3b / Frederick, MD / 21701
Robin A Robinson in the U.S., Public Records Index, 1950-1993, Volume 2
Name : Robin A Robinson
Birth Date : 19 Apr 1955
Address : 917 E Academy St / Canton, Mississippi, USA / 39046-4802
https://www.whitepages.com/name/Robin-A-Mrobinson/Washington-DC/PL3NOmDvbE8
2022-11-15-whitepagess-com-report-paid-robin-a-robinson-washington-dc.pdf
Robin A Mrobinson / (Robin Augustus Robinson, Robin M Robinson)
BIRTHDATE : 10/7/1957 (65yrs)
LOCATION : Washington, DC
Addresses
(CURRENT) 1931 18th St SE Apt 3 / Washington, DC 20020
104 Michigan Ave NE / Washington, DC 20017
104 Michigan Ave NE Apt 43C / Washington, DC 20017
917 E Academy St / Canton, MS 39046-4802
584 Highway 307 / Shelby, AL 35143-5622
11 Jenna Ln / Rehoboth Beach, DE 19971-2720
PO Box 55523 / Washington, DC 20040
1349 Randolph St NW # Bs / Washington, DC 20011
1349 Randolph St NW / Washington, DC 20011
2009 37th St SE Apt 101 / Washington, DC 20020
1361 Downing St NE / Washington, DC 20018
20419 Peach Tree Rd / Dickerson, MD 20842
PO Box 83 / Canton, MS 39046
814 Ivy Way / Frederick, MD 21701
8960 Congress Pl / Landover, MD 20785
22 Fifeshire Ct / Montgomery Village, MD 20886
10234 Betty Jane Ln / Dallas, TX 75229
Robin Augustus Robinson in the U.S., Index to Public Records, 1994-2019
Name : Robin Augustus Robinson / [Robina A Robinson]
Birth Date : Apr 1955
Residence Date : 1999-2020
Address : 20419 Peach Tree Rd / Dickerson, Maryland, USA / 20842
Second Residence Date : 1985-2011
Second Address : 10234 Betty Jane Ln / Dallas, Texas, USA / 75229
Third Residence Date : 1998-2010
Third Address : 108 Sharpstead Ln / Gaithersburg, Maryland, USA / 20878
Fourth Residence Date : 1996-2006
Fourth Address : 1361 Downing St Ne / Washington, District of Columbia, USA / 20018
1976 (May 20) - Graduating college
https://www.newspapers.com/image/743263260/?terms=%22robin%20a.%20robinson%22&match=1
1983 (June 26) - Marriage to Sara Linda "Cindy" Noble
https://www.newspapers.com/image/181243356/?terms=%22robin%20augustus%20robinson%22&match=1
1983-06-26-the-clarion-ledger-jackson-ms-pg-10e.jpg
1983-06-26-the-clarion-ledger-jackson-ms-pg-10e-clip-robin-robinson-wedding.jpg
